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Flutamide was the first pure nonsteroidal antiandrogen (NSAA) compound discovered.
Following oral administration, flutamide is readily metabolized to its active metabolite 2-hydroxyflutamide that appears to be mainly responsible for the pharmacological effect (Brogden and Chrisp, 1991; Farthing et al., 1994) . It acts as a competitive antagonist that blocks the growth-stimulating effects of androgens (testosterone and dihydrotestosterone) at the androgen receptor in the prostate (Brogden and Chrisp, 1991; Labrie, 1993) and has been widely used in the treatment of prostate cancer since the 1970's. Cancer itself represents the second leading cause of death in men and prostate cancer alone ranks number five in overall causes of death among United States men (Chan et al., 2004) .
Some patients treated with flutamide orally have developed severe hepatic dysfunction at doses above the recommended, i.e. 250 mg three times daily, and minor hepatoxicity has been documented with oral doses as low as 250-375 mg/day (Ibanez et al., 2005) . Since the dysfunction seems to be dose dependent and the liver has been reported to recover after flutamide withdrawal (Aizawa et al., 2003) an improved characterization of the flutamide metabolism may contribute to the understanding of this safety issue. Both flutamide and potentially formed toxic metabolites have been proposed to be responsible for these negative effects, possibly due to affected mitochondrial respiration (Fau et al., 1994; Aizawa et al., 2003; Takashima et al., 2003; Thole et al., 2004) .
Phase I metabolites have been identified in vitro (Shet et al., 1997) and in vivo in plasma and urine from humans (Katchen and Buxbaum, 1975) . It has been shown that CYP1A2 is the dominant enzyme forming 2-hydroxyflutamide, but CYP1A1 and CYP1B1 may also be involved (Shet et al., 1997) . The formation of 4-nitro-3-(trifluoromethyl)-aniline (Flu-1), a metabolite produced by carboxyesterase, has been suggested to be directly involved in the toxicity (Aizawa et al., 2003) . Katchen and Buxbaum, who treated urine from flutamide This article has not been copyedited and formatted. The final version may differ from this version. ) patients with glucuronidase and sulfatase, were the first to propose conjugation reactions (Katchen and Buxbaum, 1975) , and later a sulfate conjugated metabolite was recovered in urine from rats (Asakawa et al., 1995b) . However, to our knowledge, intact phase II metabolites of flutamide have not been previously identified in humans. A schematic presentation of the phase I metabolites already identified together with their short names are provided in Figure 1 .
In this study liquid chromatography (LC) electrospray ionization (ESI) tandem mass spectrometry (MS/MS) was the analytical technique used, and the mass spectral data obtained for the metabolites were compared to those of the available synthetic standards. Detection by mass spectrometric methods allows low detection limits and high selectivity, and by the use of tandem MS structural information about the compounds can be obtained. A complementary technique to determine the elemental composition of drugs and their metabolites is accurate mass determination by high resolution MS. Since a smaller experimental mass error results in a smaller set of possible elemental compositions, accurate mass determination is very useful in structural evaluation of drug metabolites.
The aim of the present study was to qualitatively evaluate the in vitro metabolism of flutamide in liver microsomes from the four species dog, human, pig and rat and to compare the qualitative aspects of metabolism of flutamide in pig liver and prostate microsomes.
Secondly, the in vivo metabolism of flutamide was investigated by identification of metabolites in urine from prostate cancer patients treated with oral doses of flutamide, and a new metabolic scheme is proposed.
This article has not been copyedited and formatted. The final version may differ from this version. 
Methods

Chemicals
Sigma (Steinheim, Germany) supplied the synthetic standards of flutamide and 4-nitro-3-(trifluoromethyl)-aniline, MIKROMOL GmbH (Luckenwalde, Germany) supplied the synthetic standard of 2-hydroxyflutamide, and β-glucuronidase 1585665 from E. coli K12 was purchased from Roche, Sweden. NADPH regenerating system solution A and B (No 451220 and 451200, respectively) were purchased from BD Bioscience (Stockholm, Sweden).
The water was purified using a Milli-Q water purification system (Millipore, Bedford, MA, USA). All other chemicals were of analytical grade or better and used without further purification.
Microsomal origin, preparation, and incubation
Liver microsomes from human (male), dog (male), and rat (male) were purchased from In vitro Technologies Inc. (Baltimore, Maryland, USA). Pig (male) liver and prostate microsomes were prepared as described elsewhere (Andersson et al., 1985; Norlin, 2002) .
Incubations of liver microsomes from humans, dogs, pigs, and rats were performed at 37°C for 120 minutes. Microsomes from pig liver and prostate were incubated at 37°C for 80 minutes. All experiments were started by preincubation of Tris buffer (50 mM, pH 7.4) with microsomes (1 mg/ml) and flutamide or 2-hydroxyflutamide (5 µM in methanol) at 37 °C.
The reaction was initiated by the addition of NADPH regenerating systems (50 µl of solution A and 10 µl of solution B, the total volume was 1 ml). The incubations were terminated by the addition of two volumes of ice-cold methanol.
Sample preparation
Microsomes
After termination of the incubation 1 ml was removed and centrifuged at 3,600 rpm for 10 minutes and the supernatant was transferred to a fresh test tube and evaporated to dryness under nitrogen at 60°C. The residue was dissolved in 100 µl 0.1% formic acid/acetonitrile (75:25) and transferred to an LC vial before analysis.
Prostate cancer patient urine
After individual approval, urine from three prostate cancer patients was collected prior to curative brachytherapy. The patients were treated with oral 250 mg (bid) doses of flutamide and were at steady state plasma level of 2-hydroxyflutamide (the active metabolite). They had not taken any other drugs considered likely to interfere with the analysis.
Prior to the analysis of phase I metabolites, the urine was treated with β-glucuronidase. To 3 ml of urine, 1 ml of potassium phosphate buffer (0.1 M, pH 6.1) was added and pH was measured to 6.6. β-glucuronidase was added (75 µl) and the test tubes were placed in a water bath for one hour (50°C, horizontal shaking). After centrifugation (3,600 rpm, 10 minutes) the supernatant was transferred to LC vials.
The urine was treated in the same way except for the addition of β-glucuronidase in the search for conjugates with glutathion, sulphate, and glucuronic acid. The mass spectrometer used for the accurate mass measurements was an electrospray ionization (ESI) hybrid quadrupole/time of flight instrument (Q-Tof Model I, upgraded with a 3.6 GHz time-to-digital converter card, Micromass, Manchester, UK) equipped with an orthogonal electrospray source (Z spray) operated in the negative ion mode. The source block and desolvation temperatures were 120 and 350°C, respectively, the capillary and cone voltage were -3000 and -40 V, respectively, and argon was used for collision-induced dissociation (CID, the inlet pressure was set to 20 psi).
Calibration was performed every day by a constant infusion of a sodium iodide solution (2 mg/ml in 2-propanol/water 50:50) at 1 µl/min. The argon gas was turned on and the collision energy was set to 4 eV when data was collected for one minute from m/z 100 and m/z 800. Spectra were combined and smoothed. To make sure that no dead time distortion was present the TOF constants, resolution and number of pushes correction factor (Np multiplier), were first set to zero. Then the procedure was repeated with the TOF constants set to 5000 and 0.7 for resolution and Np multiplier, respectively (m/z values for both centered spectra should be the same). According to the recommendations from the manufacturer, a polynomial of order four was used for the calibration. µl/min through a T-connection, where it was mixed with the LC mobile phase (see above).
The software Masslynx version 3.4 (Micromass Ltd., Manchester, United Kingdom) combined the spectra and the internal calibrant peak (lock mass) was chosen in order to be as close as possible to the m/z of the sample peak of interest. The software allowed the use of one lock mass only. The dead time distortion was evaluated as above.
Triple quadrupole mass spectrometry
The system described below was used for the analysis of microsome and urine samples throughout this study. 10 (30) chromatogram. During analysis, the sheath and auxiliary gas was nitrogen at 30 and 2 mTorr pressure, respectively, the capillary temperature was 250 °C, the spray voltage was -3000 V, and the collision energy was 22 V unless otherwise stated.
The search for metabolites
The search for flutamide metabolites was performed manually by interpretation of mass spectra and chromatograms. Mass spectral information of samples, blank samples and synthetic standard solutions of flutamide, 2-hydroxyflutamide and 4-nitro-3-(trifluoromethyl)-aniline were compared by looking at peaks in the total ion chromatogram (TIC) and known mass shifts, for example +16 for hydroxylation and +176 for glucuronidation. Neutral loss scans of 80 and 176 was used to recognize conjugations by sulfate and glucuronic acid, respectively. In the search for glutathion conjugates neutral loss scans of 75, 129, and 146
were used.
Results
Accurate mass determination of MS/MS fragments from flutamide and 2-hydroxyflutamide standards
The fragments produced of the flutamide and 2-hydroxyflutamide standards are summarized in Tables 1 and 2 , respectively. Sternal and Nugara identified fragments corresponding to B
and E in positive fast atom bombardment (Sternal and Nugara, 2001 ) but the other fragments have not been reported in the literature before. Fragment C (I) was a common fragment for the two compounds but was produced to a greater extent from 2-hydroxyflutamide. In flutamide, D is the dominating fragment. The accurate mass data indicate that fragment D was produced by a net loss of C 3 H 7 NO, which corresponds to one propyl radical and one NO radical. The latter one could be formed from the aromatic nitro group (Madhududanan, 1996) . This fragment (m/z 202) could not be found in 2-hydroxyflutamide possibly because it is less likely that the hydroxy propyl group is lost compared to the propyl group. The loss of NO 2 and HF can be observed in both substances resulting in fragments B and K, and F and L, respectively.
In vitro metabolism in liver microsomes from dog, human, pig, and rat Two-hydroxyflutamide was the only metabolite found in the liver microsomes from all four species. Interestingly, in liver microsomes from the three animals either two or three isoforms of hydroxyflutamide were detected (Table 3) . These isomers have not previously been reported.
In rat liver microsomes M1, Flu-1, three isomeric forms of hydroxyflutamide, and two isomers of M3 were detected. (Fig. 4b) , indicating that hydroxylation can occur on either the tertiary or primary aliphatic carbon (cf. Fig. 4a ).
In liver microsomes from humans, the only metabolite found was 2-hydroxyflutamide as previously reported (Shet et al., 1997) . However, the two minor metabolites that were detected but not identified by Shet and co-workers could not be detected in this study.
Comparison between the in vitro metabolism in pig liver and prostate
The in vitro metabolism in the microsomes from pig liver and prostate were compared after incubation of either flutamide or 2-hydroxyflutamide. In liver microsomes, three mass-tocharge ratios matching known flutamide metabolites were found after flutamide incubation. and 7.5 minutes, respectively. To our knowledge, this is the first report of isomeric forms of the metabolite called Flu-3 (cf. Fig. 1 ). Hydroxylated Flu-1 might be a more correct nomenclature for the metabolites formed but in order to reduce the confusion we will continue to call the metabolite Flu-3 throughout this paper, without any conclusion of the exact position of the hydroxy group. Peaks corresponding to [M-H] -for M1 and Flu-3 were also discovered after incubation with 2-hydroxyflutamide, which indicated that those two 
Urine from patients treated with flutamide
In this present study, several phase I and phase II metabolites were recovered in urine from prostate cancer patients treated with oral 250 mg doses (bid) of flutamide ( (Kostiainen et al., 2003) . In order to identify drug metabolites by mass spectral information, the fragmentation of a synthetic standard of the drug is advantageous. We had access to synthetic standard substances of flutamide, 2-hydroxyflutamide and 4-nitro-3-(trifluoromethyl)-aniline (Flu-1) for which the retention times and fragmentation patterns could be used for the determination of metabolites in the in vitro and in vivo samples. The fragments produced from the standard were then used to draw conclusions about the structure of the metabolites that are similar in their chemical structure and thus fragmented in a similar manner. A positive ion fast atom bombardment mass spectrum of flutamide can be found in the literature (Sternal and Nugara, 2001 ), but chemical entities tend to fragment differently depending on the technique and analytical conditions applied. In this study, a hybrid quadrupole/time of flight instrument with an electrospray ion source was used for accurate mass measurements in order to assist structural assignment of the fragment ions of flutamide and 2-hydroxyflutamide standards. The fragments were produced by collision-induced dissociation and all fragments except for two could be determined within 3 mDa mass difference. In the cases of the larger mass difference the peak intensities were low in combination with a larger difference between the peak measured and the lock mass value.
This article has not been copyedited and formatted. The final version may differ from this version. 17 (30) The pharmacologically active 2-hydroxyflutamide has been reported as the major plasma metabolite of flutamide in rats (Asakawa et al., 1995a ), dogs (Farthing et al., 1994 , and humans (Katchen and Buxbaum, 1975) . This was also supported in our study as 2-hydroxyflutamide was the only metabolite found in the liver microsomes from all four species. Since 2-hydroxyflutamide is responsible for the antiandrogen effect it may be concluded that these three animal species are relevant models at least from a metabolic perspective. Furthermore, there are reports concluding that there are similarities between pig and human metabolizing systems (Anzenbacher et al., 1998; Myers et al., 2001; Soucek et al., 2001; Anzenbacher et al., 2002) . The hydroxylation has until now only been observed on the second (tertiary) aliphatic carbon which might be considered an uncommon metabolic process (Schulz et al., 1988) . However, this study shows that hydroxylation also can occur on the primary aliphatic carbon as well as on the aromatic ring. The three isomers of the mono hydroxyflutamide metabolite were separated by the liquid chromatography system used. In the case of trihydroxylated flutamide, two isomers were identified in this study. In one of the metabolites all three hydroxy groups were aliphatic and in the other isomer, two were aliphatic and one aromatic.
It has been reported that the prostate tissue contains the gene transcripts of a broad array of drug and steroid-metabolizing cytochromes P450 (Finnstrom et al., 2001) . However, in the comparison of the qualitative metabolism in pig prostate and liver it is clear that the metabolism was more extensive regarding the number of metabolites formed in the liver than the prostate. An interesting observation was that the Flu-3 metabolite existed in two isomers, both of which could be found in liver and prostate microsomes after incubation with flutamide and in liver microsomes after incubation with 2-hydroxyflutamide. Until now, the 2-amino-5- urine, and feces were analyzed after administration of tritium labeled flutamide to three men.
They discovered that Flu-3 was the major urine metabolite, and that treatment of the urine with glucuronidase and sulfatase increased the extraction recovery of the total amount of tritium labeled compounds, indicating the presence of conjugated metabolites (Katchen and Buxbaum, 1975) . After administration of flutamide to rats, Flu-3 sulfate has been reported to be the major metabolite in urine and glucuronic acid conjugates have been detected in bile (Asakawa et al., 1995b) . In this study intact sulfate and glucuronic acid conjugates of Flu-3 together with glucuronides of both mono and dihydroxylated flutamide were identified in human urine for the first time. One metabolic product of a glutathione conjugate, mercapturic acid conjugate of hydroxylated flutamide, was detected in the urine samples in the present study. It has been reported that hepatocytes produce electrophilic metabolites that often are subjected to glutathione conjugation (Robert et al., 2005) . Our suggestion is that the mercapturic acid conjugate is produced from flutamide through a reactive intermediate (Fig.   5 ), which might be responsible for the toxic effects observed in numerous articles (Fau et al., 1994; Aizawa et al., 2003; Takashima et al., 2003) .
In the metabolic scheme presented by Katchen and Buxbaum in 1975, 19 (30) stepwise oxidation rather than hydrolysis (Katchen and Buxbaum, 1975; Katchen et al., 1976) . On the contrary, our findings of end stage conjugates (see Figure 5 ) clearly suggest that the isobutyryl chain does not have to be removed before conjugation and renal excretion.
Instead, it is more likely that the major part of the flutamide drug is metabolized into 2-hydroxyflutamide, which may be conjugated with glucuronic acid, or further hydroxylated and then conjugated with glucuronic acid, or hydrolyzed to Flu-1 that after hydroxylation to Flu-3 can be conjugated with either sulfate or glucuronic acid. Some part of the flutamide drug appears to be converted into a reactive intermediate that can be detoxified through glutathion conjugation. Furthermore, in a recent publication by Gao et al it was concluded that the flutamide metabolism was well characterized and they showed a metabolic scheme where the only metabolites were 2-hydroxyflutamide and Flu-1 further metabolized into Flu-3 (Gao et al., 2006) . We disagree that the metabolism of flutamide was well characterized before the present publication. As an example, we were able to clearly demonstrate that conjugation reactions play an important role in the flutamide metabolism.
In conclusion, the present study for the first time detected five different intact conjugates derived from flutamide in human urine, and a number of isomers of phase I metabolites were detected in liver microsomes from the three animal species studied. A similar metabolic pattern was established in microsomes from pig liver and prostate when incubated with flutamide or 2-hydroxyflutamide, and the metabolism was more extensive in the liver than the prostate in pigs, as could be expected. Liver microsomes from all four species studied formed the pharmacologically active main metabolite 2-hydroxyflutamide, which we suggest is then further metabolized before excretion, see the proposed metabolic scheme in Figure 5 . We were also able to show the formation of a mercapturic acid conjugate formed from flutamide in human urine and suggest that the reported liver effects of flutamide are due to the molecular mechanism caused by a reactive intermediate. 
Figure 7
Urine sample from a human male patient analyzed with LC-ESI-MS/MS of m/z 452.
Fragments correspond to a mercapturic acid conjugate of hydroxylated flutamide.
